Evidence map›Paper›PMID 40933609›Full record

ReviewInternational journal of pharmaceutics: X2025

Modified alginates for precision drug delivery: Advances in controlled-release and targeting systems.

Sara Masoumi Shahrbabak, Seyede Melika Jalali, Maryam Fadaei Fathabadi, Vahid Tayebi-Khorrami, Mostafa Amirinejad, Soheil Forootan, Mahsa Saberifar, Mohammad Reza Fadaei, Zohre Najafi, Vahid Reza Askari

Abstract readReview
In one paragraph

Review in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sara Masoumi ShahrbabakDepartment of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Seyede Melika JalaliDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Maryam Fadaei FathabadiDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Vahid Tayebi-KhorramiDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Mostafa AmirinejadDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Soheil ForootanPatient Safety Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Mahsa SaberifarTransplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad Reza FadaeiDepartment of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Zohre NajafiTransplant Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Vahid Reza AskariPatient Safety Research Center, Clinical Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alginates have been modified to become a suitable platform for targeted drug release, triggering advances in targeted and controlled-release systems. Alginate chemistry and various structural modifications, including ionic crosslinking, cyclodextrin-linking, and chemical carboxyl and hydroxyl group modification, such as esterification, amidation, and sulfation, are covered in this review. These modifications are aimed at enhancing drug release mechanisms, like dissolution, diffusion, water penetration, and ion exchange-based systems. Application of modified alginates in controlled-release systems is extensive, from hydrogels, bioprinting approaches, nanofiber-based systems, in-situ gelling systems, to nanoparticle systems. Targeted drug delivery utilizes passive and active targeting strategies for numerous applications, including the treatment of cancer, inflammatory disease therapy, infectious disease, and wound healing. Emerging platforms such as hydrogels and nanoparticles provide evidence of the versatility of modified alginates. However, issues regarding scalability and biocompatibility remain as obstacles. In this review, the capabilities of alginate-based delivery systems and their role in making various release mechanisms for targeted delivery are discussed in relation to the future directions for precision medicine development.

Indexed as

AlginateControlled-ReleaseModificationPrecision Drug deliveryTargeted Drug delivery

Identifiers

PMID40933609
PMCPMC12419010

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.